News Overview

The company informed the bourses and shareholders that this stake sale is a related party transaction and was duly carried at arm’s length price.

The company announced that this project will be developed under build, own, and operate model in Rajasthan.

This is eligible for 180 days of generic drug exclusivity. The company will manufacture the product at its facility situated in India.

The price increase applies to ferro grades with manganese content below 44%, at 44%, and above 44%, as per the company’s stock exchange filing.

This new feature is already available in more than 175 Indian cities, including some of the biggest metros like Delhi, Bengaluru, Chennai, Kolkata, Hyderabad, Pune, and Lucknow.

NHAI has issued an official letter dated July 1, 2025, confirming July 9, 2025, as the “Appointed Date” for the commencement of work on the project.

The first half of 2025 has been the worst for the US dollar since 1973, at the peak of the Oil Embargo

An aggressive dovish RBI and the domestic story led to funds gravitating towards mid-cap financial stocks

Indian equity indices ended on a flat note in the rangebound session on July 1.

Overall, the week reflected a shift toward growth and risk assets, supported by dovish macro signals and improving EM sentiment.